Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico

Frontiers in Pharmacology

卷:10

Alma Delia Genis-Mendoza¹  José Jaime Martínez-Magaña¹  Humberto Nicolini¹  Humberto García-Ortíz²  Francisco Barajas-Olmos²  Angélica Martínez-Hernández²  Lorena Orozco²  Omar F. Cruz-Correa³  Vanessa Gonzalez-Covarrubias³  Xavier Soberón³  Marlet Morales-Franco³ 

[1] Genomics of Psychiatric and Neurodegenerative Diseases Laboratory, INMEGEN, Mexico City, Mexico;

[2] Immunogenomics and Metabolic Diseases Laboratory, INMEGEN, CDMX, Mexico City, Mexico;

[3] Pharmacogenomics Laboratory, INMEGEN, CDMX, Mexico City, Mexico;

关键词: pharmacogenomics;    population variation;    next generation sequencing;    pharmacodynamics;    pharmacokinetics;   

DOI  :  10.3389/fphar.2019.01169

来源: DOAJ

【 摘 要 】

The identification and characterization of pharmacogenetic variants in Latin American populations is still an ongoing endeavor. Here, we investigated SNVs on genes listed by the Pharmacogenomics Knowledge Base in 1284 Mestizos and 94 Natives from Mexico. Five institutional cohorts with NGS data were retrieved from different research projects at INMEGEN, sequencing files were filtered for 55 pharmacogenes present in all cohorts to identify novel and known variation. Bioinformatic tools VEP, PROVEAN, and FATHMM were used to assess, in silico, the functional impact of this variation. Next, we focused on 17 genes with actionable variants that have been clinically implemented. Allele frequencies were compared with major continental groups and differences discussed in the scope of a pharmacogenomic impact. We observed a wide genetic variability for known and novel SNVs, the largest variation was on UGT1A > ACE > COMT > ABCB1 and the lowest on APOE and NAT2. Although with allele frequencies around 1%, novel variation was observed in 16 of 17 PGKB genes. In Natives we identified 59 variants and 58 in Mestizos. Several genes did not show novel variation, on CYP2B6, CYP2D6, and CYP3A4 in Natives; and APOE, UGT1A, and VKORC1 in Mestizos. Similarities in allele frequency, comparing major continental groups for VIP pharmacogenes, hint towards a comparable PGx for drugs metabolized by UGT1A1, DPYD, ABCB1, CBR3, COMT, and TPMT; in contrast to variants on CYP3A5 and CYP2B6 for which significant MAF differences were identified. Our observations offer some discernment into the extent of pharmacogenetic variation registered up-to-date in Mexicans and contribute to quantitatively dissect actionable pharmacogenetic variants in Natives and Mestizos.

【 授权许可】

Unknown